MIGUEL A. SANZ, M.D.; JESUS A. MARTINEZ, M.D.; JUAN BESALDUCH, M.D.; JAVIER RAFECAS, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: In their interesting paper on heterogeneity of pathogenetic mechanisms in aplastic anemia and their therapeutic implications, Abdou and colleagues (1) have emphasized the role of immune mechanisms in some patients. They reviewed the few reports on in-vitro studies and therapeutic approaches that supported an immune pathogeneity. Only plasmapheresis, cyclophosphamide, and antilymphocyte globulin were considered for therapeutic trials. Recently another immunologic therapeutic approach has been devised: administration of a high dose of methylprednisolone (2). The results of this preliminary report, which described bolus therapy, induced us to give the same treatment to a selected group of patients with
SANZ MA, MARTINEZ JA, BESALDUCH J, et al. Bolus of Methylprednisolone for Aplastic Anemia. Ann Intern Med. 1982;96:124. doi: https://doi.org/10.7326/0003-4819-96-1-124_1
Download citation file:
Published: Ann Intern Med. 1982;96(1):124.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use